efficiency and potency in clinical trials in humans to act as a useful adjunctive therapy for the surgical removal of CNS tumors. Therefore, it remains a worthwhile exercise to continue exploring additional therapeutic strategies to treat brain tumors.
A recent addition to the list of viruses being considered for oncolytic therapy is VSV, a prototype virus for the Rhabdoviridae family. 3, 4, 9, 32 Vesicular stomatitis virus causes rapid induction of apoptosis and cell death. 11, 17, 21 Furthermore, its replication cycle is extremely fast, and infectious progeny virus released from cells can be detected as soon as 2 to 3 hours postinfection. The matrix protein of VSV is primarily responsible for the cytopathic effects associated with a VSV infection, including inhibition of host cell transcription, inhibition of nuclear-cytoplasmic export of host messenger RNAs, and disassembly of the host cytoskeleton. Cytopathic effects typically occur 4 to 6 hours postinfection. Therefore, the rapid replication cycle of VSV coupled with the inherent cytotoxic properties of the matrix protein makes it an ideal candidate for use as an oncolytic therapy agent. Another property that makes VSV a clinically promising oncolytic agent is its ability preferentially to infect and replicate in a wide variety of tumor cell types that lack a functional IFN signaling system. 4, 9, 32 The preferential replication of VSV in tumor cells results from the apparent inability of malignant cells to produce and/or respond to IFN␤ treatment. Because it is highly sensitive to the antiviral effects induced when healthy cells are treated with IFN␤, VSV appears to be a naturally oncolytic virus whose replication properties can be exploited to eliminate tumor cells in vivo while selectively limiting replication and damage of healthy tissue.
In this study, we evaluated the oncolytic properties of VSV in a brain cancer model. More specifically, we developed an in vitro organotypic brain tissue slice-glioma coculture system in which selected CNS tissues were maintained and placed in culture as a unit. The culture conditions induced physiologically appropriate innervation of the tissues, which have electrophysiological properties similar to those in an intact brain. When rat C6-GFP or human U87-GFP glioma cells were seeded onto the tissue slice, solid tumor masses developed and spread through the tissue in a manner similar to that seen in vivo. This model is a powerful tool in studies of the CNS because it realistically approximates cellular, architectural, and physiological aspects of the in vivo brain. 2, 7, [12] [13] [14] 23, 30, 33, 36, 42 Using this coculture model, we verified the oncolytic properties of rVSV-wt, which had been reported previously by others, but we also showed that there is unwanted toxicity even when virus replication is inhibited by IFN␤ pretreatment. Importantly, we demonstrated that a replication-restricted rVSV-⌬G can significantly reduce tumor load while causing little damage to healthy cells and tissues in the coculture model, indicating that rVSV-⌬G vectors can be used as an efficacious alternative to rVSV-wt in cancer therapy. Our data provide a framework for future animal studies directed toward developing rVSV vectors as adjuvants to surgery in the treatment of high-grade gliomas of the CNS.
Materials and Methods

Cells and Cell Culture
The C6 rat glioma cell line (American Type Culture Collection, Manassas, VA) was maintained as a monolayer culture at 37˚C in 5% CO 2 in Hams/F12 medium supplemented with 15% heat-inactivated horse serum, 2.5% heat-inactivated FBS, 100 U/ml penicillin, and 100 g/ml streptomycin. The U87 human glioma cell line (American Type Culture Collection) was maintained as a monolayer culture at 37˚C in 5% CO 2 in Dulbecco modified Eagle medium supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 g/ml streptomycin, 2 mM/L glutamin, 1X nonessential amino acid solution, and 10 mM HEPES. Both cell lines were stably transduced using the pFB retrovirus (Stratagene, La Jolla, CA) expressing GFP to allow for enhanced visual analysis. Cells stably transduced with GFP were sorted using flow cytometry to generate a cell population homogeneously expressing high levels of GFP. To prepare the cells for seeding onto the brain tissue slices, cells in exponential growth were harvested using ethylenediamine tetraacetic acid and trypsin for 5 minutes at 37˚C. Trypsinization was terminated with the aid of complete medium described earlier, and the cells were centrifuged for 5 minutes at 1000 rpm. The pellets were resuspended in sterile PBS at a concentration of 3 ϫ 10 4 cells/l and counted using trypan blue staining methods. The cells were placed on ice before being seeded onto the brain tissue slices.
Generation of rVSV Expressing DsRed
To follow viral infection in real time we constructed an rVSV that expresses the cDNA for the red fluorescent protein, DsRed, which is a commercially available chromoprotein derived from a colored sea anemone (Discosoma species; BD Biosciences-Clontech, Palo Alto, CA). The cDNA for the DsRed protein was excised from the parent plasmid and subcloned into the multiple cloning site of pVSV-MCS 2.6, which is the parent vector to pVSV-⌬G-GS HA /GFP, as described previously. 31 The resulting recombinant virus, rVSV-DsRed, was recovered and characterized using standard protocols previously established in our laboratory and described elsewhere. 18 To construct rVSV-⌬G-DsRed we subcloned the cDNA for DsRed into the multiple cloning site of pVSV-⌬G-PL, 31 located upstream of the L gene. The virus rVSV-⌬G-DsRed was then recovered using methodologies described previously. 31 Because rVSV-⌬G does not encode the viral glycoprotein, virus is propagated in cells transiently expressing VSV glycoprotein(protein). Therefore, infection of cells uses VSV glycoprotein(protein)-complemented virus.
In Vitro Cytotoxicity Assay in Rat C6-GFP Gliomas
Rat C6-GFP glioma cells were placed in triplicate in 96-well flatbottom plates at 30, 60, and 90% confluency in a 100 l total volume of Hams/F12 medium supplemented with 100 U/ml penicillin, 100 g streptomycin, 15% horse serum, and 2.5% FBS. Cells were incubated overnight at 37˚C to allow for adherence. The cultures were inoculated with varying amounts (10-10 5 pfu) of rVSV-DsRed. Following the addition of the viral inoculum, cell death was analyzed at 4, 8, 24, 36, 48, 72 , and 96 hours postinfection by performing the CellTiter 96R nonradioactive cell proliferation assay (item no. G5421; Promega, Madison, WI). In this test, the compound MTS was mixed with the electron coupling reagent phenazine methosulfate at a ratio of 20:1 and was added to the 96-well plate culture. The MTS reagent was converted into an aqueous soluble formazan by dehydrogenase enzymes in metabolically active cells. Thus the number of living cells is directly proportional to the amount of formazan produced, which is read at 490 nm. The percentage of viable cells present in the culture at each time point was calculated for each condition by comparing the absorbance value at 490 nm from the MTS assay with untreated control cells by using a plate reader (Multiskan Biochromatic ELISA plate reader; Lab Systems, Vienna, VA). All reported values represent the mean of three data points.
Organotypic Brain Tissue Slice Culture, Brain Slice-Glioma Coculture, and rVSV Treatment of Brain Slice-Glioma Coculture
Our methods were modified from those introduced by Plenz and Kitai. 26 In brief, 1-to 2-day-old Sprague-Dawley rats were decapitated and the brains were removed rapidly. These brains were kept in Gey balanced salt solution (item no. G9779; Sigma-Aldrich Corp., St. Louis, MO) with 0.5% dextrose at 4˚C, and then coronal slices were sectioned on a vibratome at a thickness of 500 m for the striatum and substantia nigra and 400 m for the cortex. The slices with areas of interest were cut with the aid of a dissecting microscope. The areas of cortex, striatum, and substantia nigra pars compacta were dissected into 0.5 to 1 mm in size, subsequently placed on a culture insert (Millicell, item no. PICM03050; Millipore Corp., Billerica, MA), and submerged in 10 l of chicken plasma (item no. P3266; Sigma-Aldrich Corp.) on a coverslip. After carefully aligning the tissue on the insert, 0.5 U bovine thrombin (item no. T6634; Sigma-Aldrich Corp.) in 10 l of Gey-dextrose solution was added and mixed with the chicken plasma on the coverslip. The coverslip with the brain tissue was then placed into a culture tube (item no. 156758; Nalge Nunc International, Rochester, NY), and to each tube was added 750 l incubation medium with the following components (all from Invitrogen Corp., Carlsbad, CA): 50% basal medium Eagle (item no. 21010-046), 25% Hanks balanced salt solution (item no. 24020-125), 25% horse serum (item no. 26050-070), 1 mM L-glutamine (item no. 25030-081), and 0.5% dextrose (item no. 15023-021). The tubes were then incubated at 35˚C on a carousel rotated at a speed of 0.5 rpm. After 72 hours in culture, a mitosis inhibitor mix consisting of 4.4 M each of cytosine-␣-D-arabinofuranoside, uridine, and 5-fluoro-2Ј-deoxyuridine was added to the culture medium. This medium was removed after 24 hours and replaced with 750 l of fresh medium. Thereafter, the culture medium was completely replaced twice a week. Tissue slices were used for experiments after having been in culture for 3 weeks.
To generate brain slice-C6 or -U87 glioma cocultures, 150,000 glioma cells in a volume of 5 l were delivered onto the tissue slice by using sterile conditions. The culture tube without culture medium was placed horizontally in the incubator for 30 minutes. The culture medium was then added, and the tube was left in a horizontal position for another 2 hours before resuming its revolutions on the carousel. The growth of C6-GFP or U87-GFP glioma cells in culture was visualized daily with the aid of an Olympus fluorescence microscope, and the images were collected using a digital camera.
Viral Treatment of Brain Tissue Cultures With and Without IFN␤
The brain tissue remained in culture for at least 3 weeks and was then inoculated with rat C6-GFP or human U87-GFP glioma cells. The brain slice alone or brain slice-glioma coculture was then infected with 10 4 pfu rVSV-DsRed or 10 6 IU infectious ⌬G-DsRed viruses. The viruses were adsorbed onto the brain tissue slices for 5 hours at 37˚C while on the carousel. The inoculum was then removed, the tissue slices were rinsed in medium, and fresh medium was added to the tissues. These tissue slices were then incubated for an additional 3 days. Some tissues were pretreated with 1000 U of rat IFN␤ at 18 to 20 hours prior to viral infection. Once the virus had been delivered, it was then adsorbed in the presence of IFN␤, as described earlier. The inoculum was then replaced after 5 hours with fresh medium also containing 1000 U IFN␤.
Immunohistochemical Analysis
The tissue slices were fixed in 4% paraformaldehyde in phosphate buffer for 2 hours and were washed with PBS three times before they were mounted onto glass slides. The cultured tissue was dried on a hotplate briefly and stored at 4˚C for later use. Immunohistochemical analysis was performed using the following procedures. The slides were briefly rinsed in PBS; treated with 3% hydrogen peroxidase and 10% methanol for 20 minutes together with three subsequent rinses with PBS; incubated in 2% nonfat milk and 0.3% Triton-X in PBS for 1 hour; incubated in mouse anti-MAP2 (1:500, item no. M-4403; Sigma-Aldrich Corp.) or mouse anti-TH (1:1000, item no. MAB318; Chemicon International, Temecula, CA) with 3% donkey serum and 0.1% Triton-X overnight at room temperature; washed with PBS three times; incubated in Cy2-or Cy3-conjugated AffiniPure donkey anti-mouse immunoglobulin (1:250; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) with 2% donkey serum and 0.1% Triton-X for 4 hours at room temperature in the dark; washed with PBS three times; dehydrated through graded ethanol; cleared with xylene; and mounted with a coverslip in DPX mounting medium (item no. 44581; Fluka Biochemika, Buchs, Switzerland). The MAP2 and TH immunoreactivity was visualized using a BioRad confocal microscope, and digital images were collected using the associated confocal software. The extent of viral infection in the brain tissue slices was visualized by following DsRed expression with the aid of a fluorescence microscope.
Electrophysiological Recordings
The brain tissue cultures were transferred from the culture tubes to a recording chamber superfused with artificial CSF at a temperature of 34 to 35˚C. The artificial CSF contained (in mM) 126 NaCl, 2.5 KCl, 1.2 CaCl 2 , 1 MgCl 2 , 0.4 MgSO 4 , 0.3 NaH 2 PO 4 , 0.3 KH 2 PO 4 , 26 NaHCO 3 , and 11 D-glucose, and was saturated with 95% O 2 and 5% CO 2 . Whole-cell recordings were obtained from neurons in the cortex with the aid of an Olympus BX50WI upright microscope (Olympus, Lake Success, NY) for visual control. A low-power objective (4ϫ) was used to identify gross structures in the tissue cultures, and a 40ϫ water immersion objective coupled with Hoffman optics was used to visualize individual neurons. An Axopatch-1D amplifier (Axon Instruments, Foster City, CA) was used for current and voltage-clamp recordings. Patch pipettes were prepared from borosilicate glass by using a Flaming-Brown micropipette puller (model P-90; Sutter Instruments, Novato, CA). The pipette solution contained (in mM) 127 K-gluconate, 3 KCl, 1 MgCl 2 , 0.025 CaCl 2 , 10 HEPES, 0.1 ethyleneglycol-bis(␤-aminoethylether)-N,NЈ-tetraacetic acid, 2 adenosine triphosphate, and 0.2 guanosine triphosphate. The pH was adjusted to 7.3 by using 1 M KOH, and osmolarity was adjusted to 290 to 295 mOsm with water. Patch pipettes had resistances of 3 to 4 M⍀ when filled with the aforementioned pipette solution. Electrical signals were sampled and digitized at 10 kHz by using Digidata 1322A (Axon Instruments) and a Dell computer equipped with Clampex (version 8.2; Axon Instruments). Other software, including Origin (OriginLab, Northampton, MA) and MiniAnalysis (Synaptosoft, Decatur, GA), were used for data analysis. Ionotropic glutamate receptor antagonists, DNQX (Sigma-Aldrich Corp.), and APV (Sigma-Aldrich Corp.) were added to the perfusate when needed.
Results
Recombinant VSV-DsRed Exhibits Strong Cytotoxic Activity in Vitro Against Rat C6-GFP Gliomas
To confirm that rat C6-GFP glioma cells were susceptible to infection by rVSV encoding DsRed, we infected cells grown in a six-well dish with amounts of virus ranging from 10 to 10 5 pfu. Figure 1 shows that with the addition of 10 5 pfu to the C6-GFP glioma culture, which corresponded to a multiplicity of infection of 1, most cells demonstrated the characteristic cytopathic effects of VSV infection, that is, cell rounding and cell death by 24 hours postinfection. More than 95% cells were separated from the dish by 48 hours. Infection with a lower viral inoculum produced similar cytopathic effects, but slower kinetics (data not shown). These results confirm that rat C6-GFP glioma cells are sensitive to infection by rVSV-DsRed. Images in Fig. 1 were collected using a digital camera (Axiocam; Carl Zeiss, Inc., Thornwood, NY) mounted on a microscope (Axioskop; Carl Zeiss, Inc.).
To quantify better the degree of cytoxicity caused by rVSV-DsRed in the rat C6-GFP glioma and more specifically to define the time course of cell death, we performed in vitro cytotoxicity assays. Rat C6-GFP glioma cells were placed in 96-well flat-bottom plates at 30, 60, and 90% confluency and were infected with amounts of rVSV-DsRed ranging from 10 to 10 5 pfu. Cell death was analyzed at 4, 8, 24, 36, 48, 72, and 96 hours postinoculation by using the cell titer nonradioactive cell proliferation assay. As shown in Fig. 2 , infection with rVSV-DsRed resulted in roughly 90% cell death within 72 hours regardless of the viral titer.
The data were similar when the glioma cells were plated at 30 and 60% confluencies (data not shown). In summary, rVSV-DsRed generated excellent in vitro cytolytic activity against rat C6-GFP glioma cells irrespective of cell density or the amount of viral inoculum.
Organotypic Brain Tissue Slice-C6-GFP Coculture System for Studying the Efficacy and Toxicity of Antiglioma Therapies
To study various facets of rat brain tissue-glioma cell biology and to evaluate the effect of therapeutic agents on tumor regression and any agent-associated tissue toxicities, we developed an organotypic brain tissue slice-glioma coculture system modeled after the system developed by Plenz and colleagues. [26] [27] [28] As shown in Fig. 3 , this system involves the dissection and culture of cortex, striatum, and substantia nigra from neonatal rats. After the brain tissue slices have been in culture for 3 weeks, they display immunohistochemical and electrophysiological properties similar to those in intact brains. Once established, the cultures can be used for experiments up to 6 to 8 weeks postplating. Figure 3B demonstrates TH immunostaining indicative of mature dopaminergic substantia nigra neurons in the tissue slice. Figure 3C demonstrates baseline MAP2 immunoreactivity, which is a nonspecific neuronal marker that is a sensitive indicator of neuronal integrity and was used to monitor toxicity of rVSV in the brain slice cultures. 41 To use this culture system for the study of glioma, we inoculated glioma cells onto the tissue slices and let them grow naturally. By using glioma cells that stably express GFP, the cultures could be monitored in real time with fluorescence microscopy. After a period of 3 to 4 days, depending on the amount of rat C6-GFP glioma inoculum and the rate of tumor cell growth, the cocultures were washed with PBS and fixed with 4% paraformaldehyde in phosphate buffer. tion images of organotypic brain slice-glioma coculture, respectively.
Recombinant VSV-DsRed Toxicity and Efficacy in an Organotypic Brain Slice-Glioma Coculture Model
To test the toxicity of rVSV in healthy tissues within the culture system, we inoculated the cultures with rVSVDsRed. This recombinant virus expresses a red fluorescent protein, thus providing a signal distinguishable from the green fluorescence of the rat C6-GFP glioma cells and allowing us to monitor the viral infection in the brain tissue culture in real time. The gene for DsRed was introduced between the G and L genes in the VSV genome. Insertion of an additional foreign gene between the G and L genes has no effect on the cytolytic properties or replication efficiency of the virus. 19 Following inoculation with the virus, the tissue cultures were examined using immunohistochemical staining for MAP2 expression. The rVSV-DsRed readily infected the tissue and by the 3rd day most of the cells in the tissue slices were infected, which was indicated by the red fluorescence revealed in the tissues (Fig. 4A) . Not surprisingly, immunostaining for MAP2 on the infected slices was poor, indicating a loss of neuronal integrity (Fig. 5A) . Thus replication-competent rVSV-wt is highly cytopathic to healthy neuronal tissue and therefore its application as a CNS oncolytic agent is neither safe nor practical without some way to protect healthy tissues from VSV-associated toxicities.
It is known that VSV is highly sensitive to the antiviral effects of IFN␤. It has also been shown that malignant cells of various lineages have one or more defects in the IFN signaling pathway. 1, 39 Capitalizing on these differences, IFN␤ has recently been used to protect healthy tissue while allowing for the destruction of tumor cells by VSV-mediated cytolytic activity. 3, 32 To determine if a similar strategy could be used in the organotypic brain slice coculture system, we tested whether IFN␤ could protect the healthy neuronal tissues against rVSV infection and whether IFN␤ itself was toxic to the cells in the tissue culture. In the first series of experiments, tissue cultures were pretreated using two different concentrations of IFN␤ (100 or 1000 U) for 24 hours prior to infection with rVSV. As shown in Fig. 4 , cultures pretreated with 1000 U of IFN␤ were protected from infection with rVSV-DsRed. The MAP2 staining pattern was also dramatically improved following IFN␤ pretreatment, indicating a significant decrease in rVSV-mediated cytotoxicity in healthy tissue (Fig. 5B) and consistent with the antiapoptotic function of IFN␤. 40 Some protection was provided when the tissue slices were pretreated with 100 U IFN␤, but the level of protection was not as dramatic as that with the higher dose (data not shown). Importantly, IFN␤ alone was not toxic to the tissue slice; therefore it represents an attractive pretreatment strategy in conjunction with replication-competent rVSV (Fig. 5D) .
To test the efficacy and toxicity of rVSV-DsRed in the organotypic brain slice-glioma coculture model, approximately 1.5 ϫ 10 5 C6-GFP cells were delivered onto mature tissue slice cultures and allowed to grow on the slices for 4 days. By the 4th day the glioma cells had developed into a sizeable tumor mass. At this point the coculture was pretreated with 1000 U IFN␤ for 24 hours, followed by infection with 10 4 pfu rVSV-DsRed. After adsorption of the virus for 5 hours, the inoculum was removed, fresh medium containing 1000 U IFN␤ was added, and the culture was incubated at 35˚C for 3 days. The cocultures were monitored daily by fluorescence microscopy for a reduction in the rat C6-GFP glioma tumor load and an infection of healthy tissues by rVSV-DsRed. As shown in Fig. 4 , there was a significant reduction in tumor load in the cocultures pretreated with IFN␤ after a 3-day exposure to the virus. Furthermore, although rVSV-DsRed had excellent cytolytic activity against the tumor, very little infection of the neuronal cells in the tissue slice itself was apparent (Fig. 4D) . Thus, rVSV-DsRed appeared selectively to destroy the rat C6-GFP tumor. Interestingly, despite little apparent infection in the tissues inoculated with rVSV-DsRed and pretreated with IFN␤ cocultures, the tissue slices were still signifcantly damaged as indicated by the aberrant MAP2 immunoreactivity (Fig. 5) . Furthermore, attempts to assess the electrophysiological properties of neurons in these tissues by performing whole-cell patch recording techniques were unsuccessful (data not shown). This indicates that although rVSV-DsRed is effective in eliminating tumor cells, there was still sufficient damage to the brain tissue slice that had been mediated by mechanisms other than those directly as- sociated with the viral infection (that is, the release of inflamatory cytokines and so forth).
Replication-Restricted rVSV-⌬G is Similar to rVSV-wt in Tumor Cytolytic Activity, But is Superior With Respect to Toxicity in the Organotypic Brain Slice-Glioma Coculture
Recombinant VSV-⌬G is a second-generation, replication-restricted rVSV. It lacks the glycoprotein gene that encodes for the envelope protein of the virus. The glycoprotein(protein) of VSV mediates attachment of the virus to cells and fusion of the viral envelope with the endosomal membrane following endocytosis of the virus and, as such, is required for VSV infectivity. Therefore, to propagate rVSV-⌬G vectors, the virus must be grown in cells transiently expressing the wild-type glycoprotein(protein). The progeny viruses that are produced contain the transiently expressed glycoprotein(protein) in the viral envelope (infectious ⌬G virus) and can infect cells normally; however, because the genome of the viruses lacks the glycoprotein(protein) coding region, the progeny virions released from cells that do not express the glycoprotein(protein) are noninfectious and cannot reinfect adjacent cells. Therefore, rVSV-⌬G vectors undergo a single round of replication (that is, replication restricted). The advantage of using rVSV-⌬G in terms of toxicity is that the exponential increase in virus particles generated over time with replication-competent virus, such as rVSV-DsRed, is avoided.
To test the toxicity of replication-restricted rVSV-⌬G in the tissue slice culture system, we inoculated culture with a modified ⌬G virus encoding DsRed (rVSV-⌬G-DsRed) and examined the tissue culture after 3 days. The culture was fixed and stained for MAP2 to determine neuronal integrity following infection. We found that infectious rVSV-⌬G-DsRed readily infected the tissue in a manner similar to that with rVSV-DsRed (Fig. 6A) . Interestingly, despite the significant infection resulting from rVSV-⌬G-DsRed, MAP2 immunoreactivity remained relatively intact (Fig.  7A) . As predicted from the earlier studies, little to no infection by ⌬G-DsRed was observed when the slices were pretreated with IFN␤ (Fig. 6) , and staining for MAP2 was similar to that seen in healthy brain slice cultures (Fig. 7B) .
To test the efficacy and toxicity of ⌬G-DsRed on the brain slice-glioma coculture, we inoculated approximately 1.5 ϫ 10 5 rat C6-GFP or human U87-GFP glioma cells onto mature tissue cultures and allowed the cells to grow on these slices for 4 days. After the 4th day, when the glioma cells had developed into a sizeable tumor mass, the coculture was treated with IFN␤ at a concentration of 1000 U for 24 hours and then inoculated with 10 6 IU infectious ⌬G-DsRed virus. The virus was adsorbed for 5 hours, and then the inoculum was replaced with fresh medium containing 1000 U IFN␤. The culture was incubated at 35˚C for an additional 3 days, and the cocultures were examined daily by fluorescence microscopy for a reduction in the rat C6-GFP or human U87-GFP glioma tumor load as well as an infection of healthy tissues by ⌬G-DsRed. As shown in tivity against the tumor, there was little if any infection of healthy cells in the tissue culture itself (Fig. 6 ). Results were similar for studies performed using the brain slice-U87-GFP glioma cocultures (Fig. 6C) . Thus, IFN␤ treatment followed by infection with infectious ⌬G-DsRed appeared selectively to destroy the rat C6-GFP and human U87-GFP gliomas without infecting the healthy tissues in this coculture model. Figure 7C and D shows that ⌬G-DsRed was not toxic to healthy tissues, which was demonstrated by excellent MAP2 immunoreativity. Thus, the use of the replication-restricted rVSV-⌬G-DsRed in combination with IFN␤ pretreatment appears to be an effective combination in glioma therapy.
Treatment of Brain Slice-Glioma Coculture With Replication-Restricted rVSV-⌬G Does not Affect the Electrophysiological Properties of Neurons in the Brain Slice Culture
To determine whether the basic electrophysiological properties of neurons in the cocultures were affected by 
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discharged repetitive high-frequency action potentials with little frequency adaptation in response to a depolarizing current injection, which was characteristic of cortical fast-spiking interneurons. Two neurons (lower) fired fewer action potentials in response to the depolarizing current injection and thus appeared to be cortical pyramidal neurons. Note that rVSV-⌬G treatment did not impair the ability of the neurons to fire action potentials. B: Voltage-clamp recordings of spontaneous postsynaptic currents from neurons in control (left) and rVSV-⌬G-treated brain slice cultures (right). Recordings from neurons in normal artificial CSF (upper). Tracings of the average of 23 events detected from the control neuron (center left) and 27 events from the rVSV-⌬G-treated neuron (center right), demonstrating the similar kinetics of synaptic currents from these two neurons. The recordings were made at a holding potential of Ϫ60 mV and obtained from the same neurons as in A lower. After the addition of 10 l DNQX (10 mM) and 1 l APV (50 mM) to the recording chamber, the synaptic events were blocked in both cases, indicating that they were mediated by ionotropic glutamate receptors (lower).
treatment with IFN␤ and replication-restricted rVSV-⌬G-DsRed, we obtained whole-cell recordings from neurons in the brain slice-U87-GFP glioma coculture treated with rVSV-⌬G and compared them with recordings obtained from neurons in untreated control brain slice cultures. As shown in Fig. 8A , the ability of neurons to fire action potentials was not significantly affected by the combined IFN␤ and rVSV-⌬G treatment. The two panels on the left in Fig.  8A show membrane potential responses to intracellular injections of hyperpolarizing and depolarizing current pulses for two cortical neurons in untreated control tissue cultures. The upper panel represents responses from a fast-spiking interneuron, which displayed high-frequency repetitive firing with little frequency adaptation in response to depolarizing current pulses; the lower panel appears to represent responses from a pyramidal neuron, which displayed fewer action potentials with strong frequency adaptation. In comparison, the two panels on the right in Fig. 8A are membrane potential responses recorded from two cortical neurons in the rVSV-⌬G-treated brain slice-glioma coculture. As seen in the untreated controls, a fast-spiking interneuron showed high-frequency repetitive firing with little frequency adaptation (upper left), whereas a pyramidal neuron fired fewer action potentials on receiving depolarizing current injections (lower left). Therefore, the firing mechanisms of neurons in the rVSV-⌬G-treated brain slice cultures were not impaired. To assess whether rVSV-⌬G treatment affected synaptic transmission between neurons, we performed a voltage-clamp experiment to record spontaneous postsynaptic currents in cortical neurons. Typical examples are shown in Fig. 8B . The traces on the left were obtained from a cortical neuron in a control brain slice culture (the same neuron as in Fig. 8A lower left) , whereas the traces on the right were recorded from a neuron in rVSV-⌬G-treated tissue (the same neuron as in Fig. 8A lower right) . The downward deflections in the top traces in Fig. 8B are spontaneous synaptic currents in normal artificial CSF and are very similar in control (left) and rVSV-⌬G-treated tissues (right). Averaged traces of these currents are also shown (center) with high magnification and an expanded time scale and demonstrate no apparent difference in current kinetics between the control neuron and the neuron treated with rVSV-⌬G. The synaptic currents were blocked by the application of ionotropic glutamate receptor antagonists, DNQX and APV (Fig. 8B lower) , indicating that they were ionotropic glutamate receptor-mediated excitatory postsynaptic currents. These results demonstrated that synaptic transmission between neurons was intact following rVSV-⌬G treatment. Taken together, the current-and voltageclamp data indicated that the basic electrophysiological properties of neurons were not significantly altered by rVSV-⌬G treatment.
Discussion
We have completed preliminary studies of wild type and replication-restricted rVSV as antiglioma therapies in an organotypic brain slice-glioma coculture model. This model is ideal for these experiments because it allows for the analysis of toxicity in healthy tissues and efficacy of potential tumor therapies, which can be studied simultaneously and in real time. Prior to undertaking these studies, it had been shown by other investigators that rVSV could infect and rapidly kill rat C6 glioma cells. 3 Furthermore, Balachandran, et al., 4 demonstrated that rVSV infection of rat C6 glioma cells induced rapid apoptosis both in vitro and in vivo and resulted in the reduction of subcutaneous gliomas in nude mice. Using rVSV-DsRed we found that all cell metabolism ceased by 72 hours postinfection and that the cells showed significant cytopathic effects by 24 hours postinfection ( Figs. 1 and 2) . Similar results were found irrespective of the initial amount of virus used or the number of cells in the culture at the time of rVSV inoculation, clearly demonstrating the rapid replication and exponential spread of rVSV throughout the culture.
One of the limitations in developing models to study CNS tumors is the inherent complexity of the matrix in which these tumors develop. In particular, culture systems that mimic the environment of the intact brain while allowing in vitro evaluation of promising therapeutic approaches are limited. Ideally, all studies focused on the effect of therapeutic agents would be performed on neurons in awake and freely moving animals. The technical complexity of these types of studies makes it difficult to evaluate the efficacy of the new therapeutic agents, however. During the past 8 years, organotypic brain slice culture techniques have improved, combining the flexibility of an in vitro preparation with the complex morphological and electrophysiological characteristics of neurons that closely match characteristics found in vivo. [26] [27] [28] The organotypic brain slice culture methods used in our experiments allow the neurons to develop anatomical connections that would normally be present in vivo, but become severed when standard in vitro brain slices are prepared. This model is a powerful tool in studies of the CNS because it realistically approximates cellular, architectural, and electrophysiological aspects of the in vivo brain. 2, 7, [12] [13] [14] 23, 30, 33, 36, 42 The brain slice coculture system is therefore ideal for studies in which pharmacological, physiological, and structural manipulation of the brain tissue will be performed prior to undertaking more complex studies in animals. Furthermore, this culture system can be maintained for more than 2 months without loss of cell integrity or electrophysiological responsiveness. Importantly, this amount of time is roughly equivalent to the life span of a rodent from birth until young adulthood; therefore, the processes that occur during CNS maturation are reproduced in the tissue culture.
It is well established that rVSV can infect CNS tissues, with devastating consequences such as encephalitis leading to coma and/or death in rats. 29, 35 Indeed, when brain tissue in the organotypic brain slice culture was inoculated with rVSV-DsRed, we observed rapid and extensive infection of the healthy tissues. Analysis of this result indicates that using replication-competent rVSV-wt for glioma therapy is not practical unless one uses a strategy that does not interfere with the cytolytic effects of VSV on tumor cells. It has been proposed that IFN␤ might be an attractive choice for such a strategy because VSV replication is significantly inhibited in healthy, nontumorigenic cells treated with IFN␤. For example, it has been shown that embryonic fibroblasts lacking the IFN-inducible double-stranded RNA-dependent protein kinase receptor are extremely vulnerable to VSV infection. 5 Furthermore, mice lacking a functional IFN system succumb to the lethal cytolytic effects of VSV. 24 Although the importance of IFN␤ in a host defense response to VSV infection is understood, the critical genes responsible for inhibition of VSV replication remain largely unknown. The fact that the majority of malignant cells tested are susceptible to VSV replication in the presence of IFN␤ implies that the host defense mechanisms required to prevent this process are not present or are impaired in these malignant cells. 3, 9, 32 Regardless, these observations lead one to assert that tumor cells should be more susceptible to rVSV infection than healthy cells and that these differences could be manipulated in a protective manner by using IFN␤ in conjunction with rVSV. We studied the effects of IFN␤ pretreatment in healthy brain tissue slices and found that it dramatically blocked the replication of rVSV-DsRed in these tissues and reduced, but did not eliminate, the toxicity of rVSV as determined by MAP2 reactivity. Importantly, incubation of the slices with IFN␤ alone for up to 4 days did not appear to have any significant toxic effect on the cells or on neuronal integrity in general.
To study gliomas in the context of healthy tissues, we developed protocols for seeding the organotypic brain slice preparations with glioma cells that were GFP positive. The glioma cells were allowed to grow naturally in the tissue preparation and ultimately formed large cellular clusters. These preparations were then exposed to either replicationcompetent rVSV-DsRed or replication-restricted rVSV-⌬G-DsRed. The infection was monitored in real time by using fluorescence microscopy and brain slice integrity was evaluated with the aid of immunohistochemical methods at the end of the experiments. In this particular experiment, IFN␤ pretreatment followed by inoculation with rVSVDsRed in a brain slice-glioma coculture clearly demonstrated that rVSV could effectively destroy glioma cells growing in the brain slice, without significant infection of the tissue. Nonetheless, despite the protection provided by IFN␤ preincubation, the tissues were still significantly damaged, as determined by MAP2 immunoreactivity. Thus, toxic mechanisms other than those associated with rVSV replication were causing the tissue damage. One explanation for this observation is that although IFN␤ induces significant antiviral activity, VSV infection of IFN␤-treated cells may cause the production of secreted factors that are toxic to the delicate tissue slices in the closed environment of the tissue culture model.
In contrast to the toxicity observed when using the replication-competent rVSV, promising data have come from preliminary studies in which a second-generation rVSV-⌬G vector was used. Because rVSV-⌬G is a replication-restricted vector that induces only a single round of infection, the subsequent spread of infectious virus beyond the site of administration is prevented. Thus, rVSV-⌬G can be administered without the concern that exponential virus spread will occur and potentially lead to serious complications in vivo. In our brain slice-glioma coculture model, we demonstrated that rVSV-⌬G-DsRed together with IFN␤ pretreatment could effectively reduce the rat or human glioma tumor burden without any apparent destruction of healthy tissues. Furthermore, neuronal integrity-as measured by MAP2 immunoreactivity and electrophysiological recordings-was intact, indicating that treatment of the brain slice-glioma coculture with rVSV-⌬G-DsRed did not cause significant toxicity in healthy tissue slices. Moreover, rVSV-⌬G-DsRed was much less toxic to the tissue slices than rVSV-DsRed, even in the absence of IFN␤ and also when more infectious (100-fold) ⌬G virus was used compared with the rVSV-wt virus. In summary, rVSV-⌬G vectors appear to possess all the properties required for a safe and effective oncolytic virus, and analysis of our results indicates that additional in vivo studies are warranted.
Conclusions
By combining and adapting existing technologies, we developed an organotypic brain tissue slice-tumor coculture system for analyzing the potential use of rVSV vectors in the treatment of brain cancer. Organotypic brain slice culture is an in vitro model that allows for the simultaneous maintenance of selected CNS tissues that innervate each other in a physiologically appropriate manner and are cultured as a unit. This model is a powerful tool in studies of the CNS because it realistically approximates cellular, architectural, and physiological aspects of the in vivo brain. Using this coculture model, we demonstrated that IFN␤ pretreatment blocks infection of healthy neuronal tissue inoculated with replication-competent VSV, thus adding a layer of protection. Furthermore, we demonstrated that rVSV-⌬G that is replication-restricted can significantly reduce the tumor load while causing little physical or physiological damage to healthy brain cells and tissues. Analysis of our data supports the hypothesis that rVSV will preferentially infect and kill tumor cells in an organotypic brain-glioma coculture system. This is most likely due to defects in the antiviral responses of the tumor cells, which can be augmented to protect healthy tissues by pretreating with IFN␤. Nonetheless, our studies were not designed to account for many in vivo factors, such as perfusion and the immune system, that will inevitably affect rVSV toxicity and efficacy in the treatment of gliomas. Thus, the next important step in working with oncolytic rVSV vectors will be to transition into in vivo rodent intracranial glioma models. Nevertheless, the data presented here provide valuable information that can be used to develop animal studies and should lead to further research that will form the basis for developing rVSVs as potential adjuvants to surgery in the therapy for high-grade gliomas.
